在耐火性生殖细胞瘤中的新疗法
Noah H Richardson1, Nabil Adra
1Division of Hematology & Medical Oncology - Melvin & Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
耐火性生殖细胞瘤 (GCT) 的结果仍然很差,有效治疗方法有限. 像CAR-T细胞和抗体-药物合体这样的新疗法在正在进行的临床试验中对这些具有挑战性的GCT病例显示出有希望.
科学领域:
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
- 临床试验 临床试验
背景情况:
- 耐火性生殖细胞瘤 (GCT) 是一个重大的临床挑战,预后不佳.
- 当前救援疗法的有效性有限,需要对GCT患者探索新的治疗策略.
研究的目的:
- 审查了解耐火GCT的进展.
- 突出针对耐火性生殖细胞瘤的新疗法和正在进行的临床试验.
主要方法:
- 关于耐火GCT的文献综述.
- 对新型GCT治疗药物的当前和即将进行的临床试验的分析.
主要成果:
- 耐火性GCT患者很少通过救援化疗获得治愈.
- 包括氨酸激酶抑制剂 (TKI),化学抗原受体 (CAR) T 细胞疗法,双特异性 T 细胞参与剂 (BiTE) 和抗体-药物联合体 (ADC) 在内的研究药物代表了有前途的途径.
结论:
- 耐火性GCT的结果仍然很差,这强调了在专家中心需要专门的护理.
- 对分子抵抗机制和新型抗原向的持续研究正在扩大耐火性GCT的治疗开发.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
Treatment Resistant Cancers
